Ikuro Matsuba

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4484896/publications.pdf

Version: 2024-02-01

27	445	687220 13	713332 21
papers	citations	h-index	g-index

27	27	27	647
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections. Internal Medicine, 2022, , .	0.3	1
2	Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study. Diabetes Therapy, 2022, 13, 265.	1.2	0
3	Effects of 1â€year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2614-2622.	2.2	6
4	Survey of the current status of subclinical coronavirus disease 2019 (COVID-19). Journal of Infection and Chemotherapy, 2020, 26, 1294-1300.	0.8	13
5	Effects of ipragliflozin on the development and progression of kidney disease in patients with typeÂ2 diabetes: An analysis from a multicenter prospective intervention study. Journal of Diabetes Investigation, 2020, 11, 1248-1257.	1.1	4
6	Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study. Diabetes Technology and Therapeutics, 2020, 22, 228-234.	2.4	17
7	A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes. Journal of Clinical Medicine Research, 2020, 12, 200-208.	0.6	1
8	Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study. Journal of Clinical Medicine Research, 2019, 11, 311-320.	0.6	3
9	Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus. Journal of Clinical Medicine Research, 2019, 11, 651-663.	0.6	2
10	Effects of a novel selective peroxisome proliferatorâ€activated receptorâ€Î± modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Journal of Diabetes Investigation, 2018, 9, 1323-1332.	1.1	32
11	Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. Journal of Clinical Medicine Research, 2017, 9, 586-595.	0.6	15
12	Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study. Journal of Clinical Medicine Research, 2017, 9, 793-801.	0.6	2
13	Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIc Study. Diabetes Therapy, 2016, 7, 349-360.	1.2	5
14	Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study. Journal of Clinical Medicine Research, 2016, 8, 116-125.	0.6	34
15	Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. Journal of Clinical Medicine Research, 2016, 8, 373-378.	0.6	27
16	Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes. Journal of Clinical Medicine Research, 2016, 8, 461-471.	0.6	7
17	Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocrine Disorders, 2015, 15, 46.	0.9	39
18	Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes. Diabetes Research and Clinical Practice, 2015, 108, e42-e45.	1.1	9

#	Article	IF	Citations
19	Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study. BMC Endocrine Disorders, 2015, 15, 34.	0.9	33
20	Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients. Diabetology International, 2014, 5, 98-104.	0.7	0
21	Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study. Diabetes Research and Clinical Practice, 2014, 103, e30-e33.	1.1	12
22	Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer. Journal of Clinical Medicine Research, 2013, 5, 217-21.	0.6	25
23	Crossâ€sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper. Journal of Diabetes Investigation, 2012, 3, 252-258.	1.1	4
24	Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. Journal of Diabetes Investigation, 2012, 3, 503-509.	1.1	36
25	The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 95, e20-e22.	1.1	58
26	Fasting Insulin Levels and Metabolic Risk Factors in Type 2 Diabetic Patients at the First Visit in Japan: A 10-year, nationwide, observational study (JDDM 28). Diabetes Care, 2012, 35, 1853-1857.	4.3	19
27	Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients. Journal of Clinical Medicine Research, 2012, 4, 309-13.	0.6	41